UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

—————————

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

—————————

For the month of September 2006

 

Commission File Number: 001-31368

 

SANOFI-AVENTIS

(Translation of registrant’s name into English)

 

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

 

        Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x
Form 40-F o

        Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

        Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

       Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o
No x

       If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________ 

 

 

 

 


 

 

 

On August 31, 2006, sanofi-aventis issued the press releases attached hereto as Exhibits 99.1, 99.2, 99.3 and 99.4 which are incorporated herein by reference.

 

Exhibit List

 

Exhibit No.

Description

  
Exhibit 99.1 Press Release dated August 31, 2006: “Preliminary Injunction Ordered in Plavix® Patent Infringement Case”
Exhibit 99.2 Press Release dated August 31, 2006: “Revised Guidance for 2006”
Exhibit 99.3 Press Released dated August 31, 2006: “New Trial Date Set for Lovenox® Patent Infringement Suit”
Exhibit 99.4 Press Release dated August 31, 2006: “Sanofi-Aventis Receives a Non Approvable Letter from the FDA for Dronedarone”

 

 

 

 

 

 

 

 

 

 

 

 

 

2

 

 

 


 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Dated: September 1, 2006

SANOFI-AVENTIS
  By: /s/ Arthur Muratyan     
    Name:   Arthur Muratyan
Title:     Vice President
              Head of Legal Corporate

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3

 

 

 


 

 

Exhibit Index

 

Exhibit No.

Description

  
Exhibit 99.1 Press Release dated August 31, 2006: “Preliminary Injunction Ordered in Plavix® Patent Infringement Case”
Exhibit 99.2 Press Release dated August 31, 2006: “Revised Guidance for 2006”
Exhibit 99.3 Press Released dated August 31, 2006: “New Trial Date Set for Lovenox® Patent Infringement Suit”
Exhibit 99.4 Press Release dated August 31, 2006: “Sanofi-Aventis Receives a Non Approvable Letter from the FDA for Dronedarone”

 

 

 

 

 

 

 

 

 

 

 

 

 

4